Bookmark

Add to MyYahoo RSS

GlaxoSmithKline News

News on GlaxoSmithKline (Ticker: GSK) continually updated from thousands of sources around the net.

12 hrs ago | Common Dreams

With Possible 'Major Public Health Impact,' Malaria Vaccine Advances

An experimental anti-malaria vaccine manufactured by pharmaceutical giant GlaxoSmithKline has shown promise at preventing the mosquito-born disease among children and infants, a new study finds.

Comment?

Related Topix: Biotech, US News, Liberal Political News

16 hrs ago | Seeking Alpha

VBI Vaccines: A Company Ready For Breakthrough

VBI Vaccines: A Company Ready for Breakthrough A company that I have been accumulating shares in is VBI Vaccines .

Comment?

Related Topix: Biotech, Medicine, Corixa, Healthcare Industry, GlaxoSmithKline

21 hrs ago | BioSpace

GlaxoSmithKline's Tanzeum??? Is Now Available In Pharmacies In The U.S.

Tanzeum, a glucagon-like peptide-1 receptor agonist, is a once weekly option for patients, in combination with some other glucose-lowering medicines.

Comment?

Related Topix: Biotech, Diabetes, Insulin (generic), Humulin, Novolin, Epidemic, Natural Disasters

22 hrs ago | Live Charts

Broker tips: Barclays, Glaxosmithkline, Antofagasta...

The stock market gave a warm reaction to Barclays' first-half results on Wednesday, with analysts upbeat about the bank's better-than-expected results.

Comment?

Related Topix: Biotech, Medicine, GlaxoSmithKline, Healthcare Industry

Yesterday | This Is Money

Aviva Investors UK Equity Income:

This Income fund looks for the holy grail of providing a dividend for its investors while also owning shares that will increase in value.

Comment?

Related Topix: Biotech, Medicine, GlaxoSmithKline, Healthcare Industry, Pop/Rock

Tue Jul 29, 2014

Seeking Alpha

What Are Theravance's GSK Drugs Really Worth?

Estimating future sales of these drugs is extremely difficult and we will see how analysts have developed their models and some of the points they are likely to miss.

Comment?

Related Topix: Startups, Theravance, Biotech, Medicine, GlaxoSmithKline, Healthcare Industry

GuruFocus.com

A Look at the Week's Top Dividend Growers

During the past week, GuruFocus recognized four companies as dividend growers. In order to be qualified for this list, the company had to: The following four companies come from various industries and sectors of the market, but they all fit the necessary criteria needed to qualify them as dividend growers.

Comment?

Related Topix: Energy, CenterPoint Energy, Biotech, Medicine, GlaxoSmithKline, Healthcare Industry

Reuters

Despite strains, GlaxoSmithKline dividend seen safe for now

GlaxoSmithKline's fat dividend is under strain but Britain's biggest drugmaker is likely to scrape by without cutting payouts as it seeks to compensate investors during a bumpy reshaping of the company.

Comment?

Related Topix: GlaxoSmithKline, Biotech, Medicine, Healthcare Industry, Stanley

SchaeffersResearch.com

Analyst Downgrades: Boston Scientific Corporation, GlaxoSmithKline...

Following new developments related to the conduct of two representatives in China, GSK was hit with four bearish brokerage notes, including a downgrade to "sell" from "buy" at Liberum, and price-target cuts at Barclays, Berenberg, and Morgan Stanley.

Comment?

Related Topix: Biotech, Stanley, Day Trading, Financial Markets, Personal Finance

The Standard

China to put Glaxo investigators on trial

A Shanghai court says American and British investigators who worked for drug maker GlaxoSmithKline will stand trial Aug. 8 on charges of illegally obtaining information on Chinese citizens.

Comment?

Related Topix: Biotech

Mon Jul 28, 2014

Wall Street Journal

Investigators Tied to GSK Get Trial Date

Two foreign investigators tied to U.K. drug company GlaxoSmithKline PLC will stand trial Aug. 8 on charges of illegally purchasing personal information about Chinese nationals, a Chinese court said.

Comment?

Related Topix: Biotech

Philly.com

KIPP high-schoolers get a leg up on college with paid internships

Haley Wilson, a rising senior at KIPP DuBois Collegiate Academy, is spending days this summer in the law department at GlaxoSmithKline learning about patents, trademarks and what it takes to bring a new medicine to market.

Comment?

Related Topix: Biotech, Medicine, GlaxoSmithKline, Healthcare Industry, Startups, Alliance Tech, Tier Technologies, Consulting, Accenture, Duck Creek Technologies, Software

Reuters

UK Stocks-Factors to watch on Monday, July 28

Britain's FTSE 100 index is seen opening higher on Monday, with September futures up 0.4 percent at 0625 GMT.

Comment?

Related Topix: Financial Markets, Biotech

The Independent

Broken up? GlaxoSmithKline's real problem is getting eaten up by scandal

Note: We do not store your email address but your IP address will be logged to prevent abuse of this feature.

Comment?

Related Topix: Biotech, US News

TheStreet.com

Why GlaxoSmithKline (GSK) Stock Is Higher Today

Your browser is not supported. Please upgrade to one of the following browsers: Google Chrome Mozilla Firefox Apple Safari Microsoft Internet Explorer 8+ You may proceed to the site by clicking here , however some pages might not work correctly.

Comment?

Related Topix: Biotech, Medicine, GlaxoSmithKline, Healthcare Industry, Mozilla, TheStreet, Financial Markets

Live Charts

GlaxoSmithKline may spin off consumer healthcare arm - report

British drug giant GlaxoSmithKline may spin off its consumer health division as it tries to get to grips with increasing competition for its drugs and Chinese bribery allegations, it was reported on Monday.

Comment?

Related Topix: GlaxoSmithKline, Biotech, Healthcare Industry

Seeking Alpha

Glaxo open to spinning off consumer healthcare business

GlaxoSmithKline's chief exec has announced the possibility of spinning off the group's consumer healthcare business in the future, should it offer more value as a standalone company.

Comment?

Related Topix: GlaxoSmithKline, Biotech, Medicine, Healthcare Industry

Sat Jul 26, 2014

Barron's

At Theravance, It's Hard to Breathe Easy

Investors dumped shares of Theravance last week, sending the stock down 18% to $22.94, after GlaxoSmithKline, which distributes Theravance's flagship pulmonary-disorder treatments, reported that sales of the products fell dramatically below expectations in the latest quarter.

Comment?

Related Topix: GlaxoSmithKline, Biotech, Medicine, Healthcare Industry

AmericanBankingNews.com

GlaxoSmithKline plc's "Underperform" Rating Reaffirmed at Zacks

's stock had its "underperform" rating restated by Zacks in a research report issued to clients and investors on Friday.

Comment?

Related Topix: Biotech, GlaxoSmithKline, Medicine, Healthcare Industry

Fri Jul 25, 2014

The Motley Fool

Today's Top Health Care Headlines: AbbVie and GlaxoSmithKline

Let's take a look at today's top stories in biotech and health care. Keep an eye out for AbbVie ( AbbVie tops estimates in the second quarter AbbVie released its second-quarter results this morning, posting an Adjusted EPS of $0.82 on $4.926 billion in revenue.

Comment?

Related Topix: GlaxoSmithKline, Biotech, Medicine, Healthcare Industry

•••
•••
•••
•••
•••

Seattle Jobs

•••
•••
•••
•••